How can microglial activation be selectively enhanced for Aβ clearance while suppressing neuroinflammation?

The skeptic identified a timing paradox where microglial activation has both beneficial (amyloid clearance) and harmful (inflammation) effects. The debate did not resolve how to achieve selective modulation of these opposing functions through gut-brain interventions.

Source: Debate session sess_sda-2026-04-01-003 (Analysis: sda-2026-04-01-003)

Resolved when an evidence artifact identifies strategies to selectively enhance microglial Aβ clearance while suppressing neuroinflammation, with one of: (1) phenotype-selective screening — treating iPSC-derived microglia with a library ofmicroglial modulators (n >= 200 compounds, including TREM2 agonists, CSF1R ligands, and repurposed drugs), measuring both Aβ phagocytosis (fluorometric Aβ42 uptake assay, >=30% increase) and inflammatory cytokine release (IL-1β, TNFα, IL-6; >=50% reduction) in the same wells, identifying compounds with dual selectivity; (2) gut-brain axis intervention studies — administering microbiota-derived short-chain fatty acids (butyrate, propionate, acetate at 50-200 mg/kg) or probiotic formulations to 5xFAD mice, demonstrating that specific microbiota or metabolite changes shift microglial phenotype (>=40% increase in M2 markers CD206/Ym1, >=30% decrease in M1 markers) while increasing Aβ clearance (>=20% reduction in insoluble Aβ40/42) without worsening inflammation; (3) temporal targeting studies showing that microglial activation timing determines beneficial versus harmful effects, with pharmacological or genetic scheduling of activation achieving >=2-fold therapeutic index in mouse behavior or pathology readouts.